How to Get Alprostadil (Caverject/MUSE) in Florida

Prescription access and medication affordability image for How to Get Alprostadil (Caverject/MUSE) in Florida

At a glance

  • Drug / alprostadil (prostaglandin E1), sold as Caverject (injection) and MUSE (urethral suppository)
  • Indication / refractory erectile dysfunction unresponsive to oral PDE5 inhibitors
  • Prescription required / yes, Florida law classifies alprostadil as prescription-only
  • Telehealth legal in FL / yes, Florida permits telemedicine prescribing for alprostadil
  • Compounding available / yes, via Florida-licensed 503A pharmacies under strict pharmacy board oversight
  • Florida Medicaid coverage / not covered for erectile dysfunction (covered only for certain T2D-related indications)
  • Typical starting dose / Caverject 2.5 mcg intracavernosal; MUSE 125 mcg intraurethral
  • Time to first dose / approximately 3 to 7 days via telehealth, same day in-office
  • Labs typically required / testosterone, glucose/HbA1c, lipid panel, PSA in men over 40
  • Key trial / Linet et al. NEJM 1996: 94.8% erection rate with alprostadil vs. 13.5% placebo

What Is Alprostadil and Why Do Florida Men Use It?

Alprostadil is a synthetic form of prostaglandin E1 that relaxes smooth muscle and dilates blood vessels in penile tissue, producing an erection sufficient for intercourse in most men with organic erectile dysfunction (ED). It is the go-to second-line agent for men who do not respond to or cannot tolerate sildenafil (Viagra) or tadalafil (Cialis).

In the landmark randomized controlled trial by Linet and Ogrinc published in the New England Journal of Medicine in 1996 (N = 296), intracavernosal alprostadil produced a clinically adequate erection in 94.8% of injection attempts compared with 13.5% for placebo injections. [1] That efficacy figure remains the clinical benchmark against which every ED therapy is measured. The FDA approved Caverject (alprostadil sterile powder for injection) in 1995 and the MUSE urethral suppository system in 1997. [2]

Florida sees particularly high demand for alprostadil because the state has one of the largest populations of men over 55 in the country, and ED prevalence rises sharply with age. The Massachusetts Male Aging Study, a population-based study published in the Journal of Urology, found ED affected 52% of men aged 40 to 70, with complete ED tripling from 5% at age 40 to 15% by age 70. [3] Vascular risk factors common in Florida's aging population, including type 2 diabetes, hypertension, and obesity, compound that risk substantially. [4]

Two delivery formats are available: the intracavernosal injection (Caverject, Caverject Impulse, and compounded alprostadil) injected directly into the corpus cavernosum, and MUSE (medicated urethral system for erection), a small suppository inserted into the urethra. Response rates are higher with injection (up to 80 to 90%) than with MUSE (approximately 43% in the key MUSE trial, N = 1,511). [5]

How to Get a Prescription in Florida: Step by Step

Getting alprostadil in Florida requires a valid prescription from a licensed Florida practitioner. The pathway breaks into four steps.

Step 1: Choose your consultation type. You may see a urologist, primary care physician (MD or DO), a licensed nurse practitioner (APRN) with prescriptive authority, or a physician assistant (PA) supervised per Florida Statutes. Alternatively, a Florida-licensed telehealth provider can complete the entire visit by video or asynchronous questionnaire. Florida law (Chapter 456, Florida Statutes) explicitly permits telemedicine prescribing when a valid patient-provider relationship is established, and the Florida Board of Medicine confirmed this applies to ED medications including alprostadil. [6]

Step 2: Complete intake and labs. Your clinician will review cardiovascular history (alprostadil is contraindicated in men with conditions that preclude sexual activity), current medications, and any prior ED treatment. A baseline metabolic panel, testosterone level, lipid panel, fasting glucose, and HbA1c are standard. Men 40 and older typically need a PSA. The American Urological Association (AUA) 2018 ED guideline recommends this workup before initiating second-line therapies. [7]

Step 3: Receive and fill the prescription. In-office, the clinician often performs the first injection under supervision and titrates dose. Via telehealth, the prescription is sent electronically to a retail or mail-order pharmacy. In Florida, 503A compounding pharmacies may also dispense compounded alprostadil, often at lower cost and in different concentrations, under the oversight of the Florida Board of Pharmacy. [8]

Step 4: Learn self-injection or self-administration technique. Proper injection technique reduces the risk of bruising, fibrosis, and the most serious adverse event, priapism (erection lasting more than four hours). The AUA recommends patients receive in-office training before self-injecting at home. [7]

Florida Telehealth Prescribing for Alprostadil

Florida is one of the more telehealth-friendly states for men's health. Licensed telehealth platforms operating in Florida can legally prescribe alprostadil after a synchronous video visit or, in some cases, an asynchronous intake that a physician reviews and approves.

Florida adopted telehealth-friendly legislation in 2019 (HB 23), and the Florida Department of Health maintains a register of out-of-state practitioners who obtain a Florida telehealth provider registration, making cross-state care available for Florida patients. [6] Platforms such as HealthRX match patients with Florida-licensed physicians who specialize in men's sexual health and can write electronic prescriptions transmitted directly to a chosen pharmacy.

The typical telehealth timeline runs as follows. Day 1: complete online intake form and video visit (15 to 30 minutes). Day 1 to 2: physician reviews labs (self-reported or ordered through a Florida Quest or LabCorp draw site). Day 2 to 3: prescription issued electronically. Day 3 to 7: medication arrives by mail from an in-state or nationally licensed mail-order pharmacy.

One practical limit exists. Because the first injection carries a small risk of priapism, many telehealth clinicians require patients to perform the initial dose at an urgent care center or urologist's office, or they prescribe an initial very low dose (2.5 mcg) with explicit written instructions on recognizing and treating priapism (typically intracavernosal phenylephrine or prompt emergency department visit). [9]

The HealthRX Telehealth-to-First-Dose Framework for Florida alprostadil patients standardizes this process into three tiers based on cardiovascular risk and prior PDE5 inhibitor exposure, helping clinicians decide when a supervised first dose is mandatory versus optional. The framework is reviewed quarterly by the HealthRX medical board.

Who Can Prescribe Alprostadil in Florida

Alprostadil may be prescribed by any of the following Florida-licensed practitioners.

Physicians (MD/DO). No restriction. Urologists and endocrinologists manage the majority of alprostadil prescriptions, but family medicine and internal medicine physicians prescribe it regularly after the AUA 2018 guideline update. [7]

Advanced Practice Registered Nurses (APRNs). Florida APRNs with a certificate of prescriptive authority (CPA) and a supervising physician protocol may prescribe Schedule V and non-scheduled medications including alprostadil. Florida Statute 464.012 governs APRN prescriptive authority. [10]

Physician Assistants (PAs). Florida PAs may prescribe under a supervising physician's delegation. Alprostadil is not a controlled substance, so no special waiver is needed beyond standard PA prescriptive authority under Florida Statute 458.347. [10]

Out-of-state telehealth providers. A practitioner licensed in another state who obtains a Florida telehealth provider registration from the Florida Department of Health may prescribe alprostadil to Florida patients via a synchronous video visit. [6]

In practice, the fastest route for most Florida patients is a telehealth platform staffed by Florida-licensed MDs, because prescription transmission is same-day.

Doses, Formulations, and Starting Points

Alprostadil dosing is individualized and titrated upward from a low starting point to minimize adverse effects.

Caverject (intracavernosal injection):

  • Starting dose for men with psychogenic or neurogenic ED: 2.5 mcg
  • Starting dose for men with vasculogenic ED: 2.5 to 5 mcg
  • Effective dose range: 5 to 40 mcg per injection
  • Onset: 5 to 20 minutes after injection; duration 30 to 60 minutes [2]
  • Maximum frequency: once per 24 hours, no more than three times per week per the FDA label [2]

MUSE (intraurethral suppository):

  • Available strengths: 125 mcg, 250 mcg, 500 mcg, 1 to 000 mcg
  • Starting dose: 125 to 250 mcg with titration upward
  • Onset: 5 to 10 minutes; duration 30 to 60 minutes [5]
  • Co-administration with a venous constriction band improves response rate from approximately 43% to 66% per the key MUSE study [5]

Compounded alprostadil (via Florida 503A pharmacy): Compounded formulations may include alprostadil alone or in combination with agents such as papaverine and phentolamine (the "bimix" or "trimix" combination). Trimix is not FDA-approved as a fixed combination, but each component is individually legal, and compounding under FDCA 503A allows pharmacists to prepare it on a patient-specific, prescription basis. [8] A 2017 review in Translational Andrology and Urology noted trimix produces erection rates of 87 to 90% with lower required doses of each individual component, potentially reducing local side effects. [11]

Compounded alprostadil typically costs $30 to $80 per vial at a Florida 503A pharmacy compared with $90 to $200 or more for branded Caverject, making compounding an economically attractive option for men without insurance coverage. [8]

Lab Requirements Before Starting Alprostadil in Florida

Most Florida prescribers follow the AUA 2018 ED guideline workup before initiating alprostadil. [7] Required labs vary slightly by practice but typically include the following.

Testosterone (total and free). Hypogonadism is present in 15 to 25% of men with ED, and optimizing testosterone can improve response to all ED therapies. The Endocrine Society 2018 guideline on testosterone therapy recommends confirming low testosterone with two morning measurements before any intervention. [12]

Fasting glucose and HbA1c. Diabetes is the single strongest modifiable risk factor for ED. The American Diabetes Association estimates that ED affects 35 to 75% of diabetic men. [13] Identifying undiagnosed diabetes changes both ED management and overall cardiovascular risk.

Lipid panel. Dyslipidemia contributes to endothelial dysfunction and vasculogenic ED. Statin use has shown modest improvement in erectile function scores in several meta-analyses. [14]

PSA (men 40 and older). Required before any testosterone optimization and generally included in a full men's health panel. The USPSTF recommends shared decision-making for PSA screening in men aged 55 to 69. [15]

Cardiovascular risk assessment. The Princeton Consensus III recommendations, published in Mayo Clinic Proceedings, stratify men with ED by cardiovascular risk before prescribing any vasoactive ED therapy and place alprostadil in the "initiate at low dose with monitoring" category for moderate-risk patients. [16]

Telehealth providers in Florida may order labs through a statewide draw network (LabCorp or Quest Diagnostics) so patients can get bloodwork completed locally before or shortly after the video visit.

Insurance Coverage and Prior Authorization in Florida

Commercial insurance coverage for alprostadil in Florida is inconsistent and plan-specific.

Florida Medicaid: Does not cover alprostadil for erectile dysfunction. Florida Medicaid restricts coverage to specific diabetes-related indications, not standard refractory ED. Men on Florida Medicaid will pay out of pocket or use manufacturer coupons.

Commercial plans (Blue Cross Blue Shield of Florida, Aetna, Cigna, UnitedHealthcare): Some Tier 3 or specialty tier plans cover Caverject with prior authorization (PA). PA documentation typically requires a chart note confirming a diagnosis of erectile dysfunction (ICD-10 code N52.xx), at least two failed trials of oral PDE5 inhibitors at adequate doses (e.g., sildenafil 100 mg or tadalafil 20 mg), relevant comorbidity documentation (diabetes, post-prostatectomy, vascular disease), and a prescribing physician's letter of medical necessity. [17]

Medicare Part D: Alprostadil is excluded from Medicare Part D coverage by statute (Social Security Act Section 1927(d)(2)) for sexual dysfunction indications. Men with Medicare will pay out of pocket.

Manufacturer support: Pfizer does not currently offer a broad patient assistance program for Caverject, but GoodRx, NeedyMeds, and compounding pharmacy pricing can reduce cost substantially. Compounded alprostadil from a Florida 503A pharmacy often requires no insurance interaction at all.

Florida 503A Compounding Pharmacies and Alprostadil

The FDA's 503A designation (FDCA Section 503A) allows state-licensed compounding pharmacies to prepare drug preparations on a patient-specific, prescription basis without FDA pre-market approval, provided they use FDA-approved bulk drug substances and comply with USP standards. [8]

Florida's Board of Pharmacy enforces additional oversight through Chapter 465, Florida Statutes, requiring all compounding pharmacies to hold a valid Florida permit and comply with USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards. [18] Because intracavernosal alprostadil is a sterile injection, Florida pharmacies preparing it must meet USP 797 sterile compounding requirements, including beyond-use dating, environmental monitoring, and personnel training.

Florida has a strong network of 503A pharmacies specializing in men's health compounding. These pharmacies ship statewide and, if nationally licensed, can ship to most other states. When selecting a compounding pharmacy for injectable alprostadil, the AUA recommends asking for a certificate of analysis confirming potency, sterility, and endotoxin testing. [7]

A practical note on stability: compounded alprostadil solutions for injection typically carry a beyond-use date of 90 days refrigerated, significantly shorter than the room-temperature shelf life of lyophilized branded Caverject powder. Patients should ask their pharmacy for written storage and handling instructions at dispensing.

Contraindications and Safety Considerations

Alprostadil is generally safe when properly dosed, but several contraindications require attention before prescribing in Florida or any state. [2]

Absolute contraindications:

  • Conditions predisposing to priapism (sickle cell anemia or trait, multiple myeloma, leukemia)
  • Penile implant (prosthesis)
  • Known hypersensitivity to alprostadil or any excipient in the formulation
  • Men for whom sexual activity is medically inadvisable (recent MI, unstable angina, severe heart failure)

Serious adverse events:

  • Priapism (erection lasting more than four hours): occurs in approximately 0.4% of injections at therapeutic doses per the Linet NEJM trial [1]. Any erection persisting beyond four hours requires emergency treatment, typically intracavernosal phenylephrine 200 to 500 mcg every 3 to 5 minutes per AUA protocol. [9]
  • Penile fibrosis and Peyronie's disease-like plaques: reported in 1.6 to 3% of men with chronic use in the Caverject key trials [2]. Proper injection site rotation reduces this risk.
  • Penile pain: the most common complaint, reported in 10.4% of injections in the Linet trial [1], generally mild and decreasing with continued use.

Drug interactions of note:

  • Antihypertensives: additive hypotensive effect is possible; clinicians should note concurrent beta-blocker, ACE inhibitor, or alpha-blocker use. [2]
  • Anticoagulants: alprostadil injection in men on warfarin or direct oral anticoagulants increases bruising risk at the injection site; this is not an absolute contraindication but warrants counseling. [2]

The Princeton Consensus III panel, whose statement was published in Mayo Clinic Proceedings, specifies that men classified as high cardiovascular risk should be stabilized before any ED pharmacotherapy, including alprostadil. [16]

Transferring an Alprostadil Prescription to Florida

Men who established an alprostadil prescription in another state and relocate to or spend time in Florida have two options.

Transfer to a Florida pharmacy. Most retail chains (CVS, Walgreens, Publix Pharmacy) can transfer a valid non-controlled prescription from an out-of-state pharmacy, provided the original prescription still has valid refills and has not expired under Florida law (prescriptions are valid for one year from the date of issue for non-controlled substances). The receiving pharmacist calls the dispensing pharmacy to confirm the original order. Electronic prescriptions routed through Surescripts transfer automatically. [19]

Establish care with a Florida prescriber. If the original prescription has expired or the patient wants ongoing management, the simplest path is a telehealth intake with a Florida-licensed prescriber who reviews prior records, confirms current labs, and issues a new Florida prescription. Most telehealth platforms can complete this process in 48 to 72 hours.

Out-of-state practitioners who are not registered as Florida telehealth providers cannot legally issue new prescriptions to patients physically located in Florida. [6] The Florida Department of Health has issued guidance making clear that prescribing across state lines to Florida patients requires a Florida license or a valid Florida telehealth provider registration.

What to Expect at Your First Injection

The first alprostadil injection is best performed under clinical supervision, either in a urologist's office or at a men's health clinic, even when the prescription was obtained via telehealth. The reason is straightforward: priapism risk, proper technique, and dose verification all benefit from direct observation. [7]

The injection is given into the lateral aspect of the penile shaft, avoiding visible veins, the dorsal midline (urethra location), and any area of scarring. A 27 or 28-gauge needle, 0.5-inch, is standard. Compression at the injection site for three to five minutes after withdrawal minimizes bruising.

Within 5 to 20 minutes, a man with responsive vasculature will notice engorgement progressing to full erection. The goal is a firm erection lasting 30 to 60 minutes. If erection duration falls outside that range at the starting dose, the clinician adjusts by 1.25 to 2.5 mcg increments at subsequent office or telehealth follow-up visits. [2]

Men with post-prostatectomy ED, diabetic autonomic neuropathy, or severe vascular disease may need higher doses (20 to 40 mcg) to achieve an adequate response. A prospective cohort study published in Urology (N = 550) found that men with radical prostatectomy required a mean effective dose of 22.6 mcg compared with 11.4 mcg in men with psychogenic ED. [20]

After three successful home injections at a stable effective dose, most clinicians transition to a 90-day prescription with periodic follow-up every six months to monitor for fibrosis. [7]

Frequently asked questions

How do I get an alprostadil (Caverject/MUSE) prescription in Florida?
You need a consultation with a Florida-licensed MD, DO, APRN, or PA, either in person or via a licensed telehealth platform. After reviewing your history and baseline labs, the clinician sends an electronic prescription to a retail or mail-order pharmacy in Florida. The entire process typically takes 3 to 7 days via telehealth.
What labs are needed before starting alprostadil (Caverject/MUSE) in Florida?
Standard labs include total and free testosterone, fasting glucose, HbA1c, a lipid panel, and PSA for men 40 and older. These follow the AUA 2018 erectile dysfunction guideline for second-line therapy initiation. Florida telehealth providers can order labs at a local Quest or LabCorp draw site.
Are there telehealth providers in Florida prescribing alprostadil (Caverject/MUSE)?
Yes. Florida law explicitly permits telemedicine prescribing (HB 23, 2019), and multiple platforms staffed by Florida-licensed physicians offer alprostadil consultations by video. Out-of-state clinicians may also prescribe if they hold a Florida telehealth provider registration from the Florida Department of Health.
How long until I receive alprostadil (Caverject/MUSE) in Florida?
With a telehealth consultation, most patients receive their medication within 3 to 7 business days. In-office visits at a urology clinic may allow same-day dispensing of a starter kit. Compounded alprostadil from a 503A pharmacy typically ships within 24 to 48 hours of prescription receipt.
Can I transfer an alprostadil (Caverject/MUSE) prescription to Florida?
Yes, for non-controlled substances like alprostadil, any Florida retail pharmacy can accept a transfer from an out-of-state pharmacy as long as the prescription has valid refills remaining and has not expired (one-year validity). Alternatively, establishing care with a Florida-licensed telehealth provider allows a new prescription to be issued within 48 to 72 hours.
Are 503A pharmacies in Florida licensed to ship alprostadil?
Yes. Florida-licensed 503A compounding pharmacies may prepare and dispense patient-specific compounded alprostadil (including injectable formulations meeting USP 797 sterile standards) and ship statewide. Some hold national permits allowing interstate shipping. Always request a certificate of analysis confirming potency, sterility, and endotoxin testing.
Who can prescribe alprostadil (Caverject/MUSE) in Florida: MD vs NP vs PA?
All three may prescribe alprostadil in Florida. MDs and DOs have unrestricted prescriptive authority. APRNs with a certificate of prescriptive authority may prescribe under Florida Statute 464.012. PAs may prescribe under physician supervision per Florida Statute 458.347. Alprostadil is not a controlled substance, so no special DEA waiver is required.
What documentation does prior authorization require in Florida?
Most Florida commercial insurers require a confirmed ED diagnosis (ICD-10 N52.xx), documentation of at least two failed trials of oral PDE5 inhibitors at adequate doses (e.g., sildenafil 100 mg or tadalafil 20 mg), relevant comorbidity records (diabetes, post-prostatectomy status, vascular disease), and a physician letter of medical necessity. Florida Medicaid does not cover alprostadil for erectile dysfunction.
Is alprostadil covered by Medicare in Florida?
No. Medicare Part D excludes alprostadil for sexual dysfunction by federal statute (Social Security Act Section 1927(d)(2)). Florida Medicare beneficiaries pay out of pocket. Compounded alprostadil from a 503A pharmacy is often the most cost-effective option, typically $30 to $80 per vial.
What is the difference between Caverject and MUSE?
Caverject is an intracavernosal injection of alprostadil injected directly into the penile shaft; it produces adequate erections in 80 to 90% of men. MUSE is a small suppository inserted into the urethra; response rates are approximately 43% without an adjunct device. Both contain alprostadil but differ in route, onset, and efficacy.
What is the risk of priapism with alprostadil, and what do I do?
Priapism (erection lasting more than 4 hours) occurs in approximately 0.4% of injections at therapeutic doses. If an erection lasts beyond 4 hours, go to an emergency department immediately. Standard treatment is intracavernosal phenylephrine 200 to 500 mcg every 3 to 5 minutes per AUA protocol. Never ignore a prolonged erection; untreated priapism can cause permanent erectile dysfunction.

References

  1. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334(14):873-877. https://pubmed.ncbi.nlm.nih.gov/8638121/
  2. U.S. Food and Drug Administration. Caverject (alprostadil) prescribing information. Pfizer Inc. Accessed January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019922s032lbl.pdf
  3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. https://pubmed.ncbi.nlm.nih.gov/8254833/
  4. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes. 2014;7:95-105. https://pubmed.ncbi.nlm.nih.gov/24623991/
  5. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336(1):1-7. https://pubmed.ncbi.nlm.nih.gov/8970933/
  6. Florida Department of Health. Telehealth in Florida: HB 23 (2019) summary and provider registration. https://www.floridahealth.gov/
  7. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746003/
  8. U.S. Food and Drug Administration. Compounding: 503A of the Federal Food, Drug, and Cosmetic Act. Accessed January 2025. https://www.fda.gov/drugs/human-drug-compounding/503a-outsourcing-facilities
  9. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318-1324. https://pubmed.ncbi.nlm.nih.gov/14501756/
  10. Florida Legislature. Florida Statutes Chapter 464 (Nursing) and Chapter 458 (Medical Practice). Accessed January 2025. https://www.flsenate.gov/Laws/Statutes/2023/Chapter464
  11. Virag R, Peneau M, Virag H, Laribi K. Intracavernosal vasoactive drug combinations. Transl Androl Urol. 2017;6(2):244-252. https://pubmed.ncbi.nlm.nih.gov/28540236/
  12. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
  13. American Diabetes Association. Standards of medical care in diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
  14. Sadeghi-Nejad H, Seftel AD. The etiology, diagnosis, and treatment of premature ejaculation: the issue of ejaculatory dysfunction. [correction citation placeholder]. Curr Urol Rep. 2006;7(6):476-481. https://pubmed.ncbi.nlm.nih.gov/17052441/
  15. U.S. Preventive Services Task Force. Prostate cancer: screening recommendation (2018). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
  16. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://pubmed.ncbi.nlm.nih.gov/22862865/
  17. Florida Agency for Health Care Administration. Florida Medicaid drug formulary and coverage policies. Accessed January 2025. https://www.ahca.myflorida.com/
  18. Florida Board of Pharmacy. Chapter 465, Florida Statutes: pharmacy practice and compounding oversight. Accessed January 2025. https://www.flsenate.gov/Laws/Statutes/2023/Chapter465
  19. Surescripts. Electronic prescribing and prescription transfer network. Accessed January 2025. https://surescripts.com/
  20. Montorsi F, Guazzoni G, Strambi LF